Klimacka-Nawrot Ewa, Musialik Joanna, Suchecka Wanda, Petelenz Michał, Hartman Magdalena, Lichtański Paweł, Błońska-Fajfrowska Barbara
Katedra i Zakład Podstawowych Nauk Biomedycznych SUM, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej w Sosnowcu.
Wiad Lek. 2010;63(4):289-99.
The effectiveness of current standard therapy of chronic hepatitis C with pegylated interferon-alpha and ribavirin is unsatisfactory and associated with a variety of side effects. In addition to common side effects, appetite disorders and weight loss are universal problems that lead to decreased quality of life. The causes of appetite disorders are not known. The aim of the present study was to evaluate the influence of pegylated interferon-alpha 2b and ribavirin therapy on taste sensitivity, hedonic perception of taste sensations, and food preferences.
Nineteen chronic hepatitis C patients infected with genotype 1 HCV participated in the study. All patients received combined therapy with pegylated interferon-alpha 2b and ribavirin in adequate doses. The study included gustatory tests (taste recognition threshold and taste intensity with hedonic perception) using a gustometric method and an evaluation of the pleasure derived from eating. All examinations were performed before therapy and during the thirteenth week of therapy.
After 12 weeks of therapy, patient sensitivity to salty and sweet was significantly decreased (p < 0.05), and bitter was described as being more unpleasant than before the therapy (p < 0.05). Also, the therapy decreased appetite without significant changes in patients' food preferences.
We found multidirectional taste disturbances during treatment with pegylated interferon and ribavirin. The results may be useful in determining the role of taste in the development of appetite disorders in chronic hepatitis C patients treated with pegylated interferon and ribavirin.
目前聚乙二醇化干扰素-α与利巴韦林联合治疗慢性丙型肝炎的疗效并不理想，且伴有多种副作用。除常见副作用外，食欲紊乱和体重减轻是普遍存在的问题，会导致生活质量下降。食欲紊乱的原因尚不清楚。本研究的目的是评估聚乙二醇化干扰素-α2b与利巴韦林治疗对味觉敏感性、味觉快感感知及食物偏好的影响。
19例感染1型丙型肝炎病毒的慢性丙型肝炎患者参与了本研究。所有患者均接受了足量的聚乙二醇化干扰素-α2b与利巴韦林联合治疗。该研究包括使用味觉测量法进行的味觉测试（味觉识别阈值和伴有快感感知的味觉强度）以及对进食带来的愉悦感的评估。所有检查均在治疗前及治疗的第13周进行。
治疗12周后，患者对咸味和甜味的敏感性显著降低（p<0.05），且苦味被描述为比治疗前更令人不适（p<0.05）。此外，该治疗使食欲下降，而患者的食物偏好无显著变化。
我们发现聚乙二醇化干扰素和利巴韦林治疗期间存在多方向的味觉障碍。这些结果可能有助于确定味觉在接受聚乙二醇化干扰素和利巴韦林治疗的慢性丙型肝炎患者食欲紊乱发生过程中的作用。
